Systemic sclerosis is a progressive, multi-system autoimmune disorder characterized by skin fibrosis, vascular dysfunction, and extensive tissue damage. Clinicians face significant challenges managing patients with cutaneous involvement because current therapeutic options remain limited. Recent molecular research reveals that long noncoding RNAs act as critical regulators of cellular activation and extracellular matrix expansion. Specifically, investigating the biological pathways driving dermal fibrosis in systemic sclerosis offers valuable opportunities for targeted drug discovery. In this article, we examine how long noncoding RNA TUG1 functions as a competitive endogenous RNA to promote pathological fibroblast proliferation, migration, and collagen synthesis.

Understanding the Role of Long Noncoding RNA TUG1

Long noncoding RNAs play vital roles in regulating gene expression and tissue remodeling across various fibrotic conditions. Specifically, taurine-upregulated gene 1 acts as a pivotal epigenetic regulator in human dermal fibroblasts. Clinical analysis shows that TUG1 expression is significantly elevated in lesional skin samples from patients with systemic sclerosis. Furthermore, functional laboratory assays demonstrate that heightened TUG1 levels promote dermal fibroblast proliferation, enhance migration, and increase extracellular matrix synthesis. Consequently, normal resting dermal fibroblasts transition into hyperactive myofibroblasts, accelerating skin stiffening and tissue induration. Conversely, silencing TUG1 using small interfering RNAs effectively dampens these aggressive profibrotic cellular behaviors. As a result, targeting noncoding RNA expression represents a viable strategy to halt abnormal collagen accumulation. Moreover, unraveling this upstream regulator allows clinicians to understand complex signaling networks in scleroderma.

The Molecular Mechanism of Dermal Fibrosis in Systemic Sclerosis

The biological cascade driving dermal fibrosis in systemic sclerosis relies on competitive endogenous RNA interactions. Mechanistically, cytoplasmic TUG1 contains complementary binding sequences that sponge specific microRNAs, namely miR-30d-3p and miR-30e-3p. Consequently, TUG1 neutralizes these protective microRNAs, relieving their post-transcriptional repression on the transcription factor SNAI2. As a result, intracellular SNAI2 protein levels increase substantially within primary dermal fibroblasts. SNAI2 then translocates into the cell nucleus and binds directly to the promoter region of the COL1A1 gene. Therefore, direct transcriptional activation of collagen genes accelerates, leading to overwhelming type I collagen synthesis and matrix deposition. This comprehensive regulatory mechanism explains how noncoding RNA dysregulation transforms resting fibroblasts into active collagen-producing cells. Ultimately, disrupting this axis offers a targeted strategy to prevent pathological matrix deposition in affected skin.

Translational Evidence from Preclinical Animal Models

To validate these cellular findings, researchers evaluated the signaling axis in bleomycin-induced animal models of dermal fibrosis. In experimental skin lesions, Tug1 expression rises significantly, matching observations in human patient tissues. Crucially, knockdown of Tug1 in vivo delivers remarkable anti-fibrotic therapeutic benefits. Specifically, Tug1 knockdown reduces skin thickness, suppresses collagen accumulation, and preserves normal dermal architecture. Mechanistically, Tug1 silencing restores free miR-30d-3p and miR-30e-3p levels in dermal tissues. Consequently, downstream SNAI2 protein levels drop, which directly decreases COL1A1 gene transcription and matrix synthesis. Furthermore, histological analysis confirms decreased myofibroblast differentiation and reduced tissue inflammation following Tug1 inhibition in experimental models. These rodent experiments confirm that targeting Tug1 effectively interrupts the pathologic cascade driving skin fibrosis. Therefore, preclinical evidence supports translating noncoding RNA targeted therapies into clinical practice.

Clinical Implications for Rheumatology and Dermatology

Identifying the TUG1/miR-30d/e-3p/SNAI2/COL1A1 axis offers major clinical implications for rheumatology and dermatology specialists. Systemic sclerosis treatment remains difficult because conventional immunosuppressive therapies mainly target active inflammation, leaving established fibrotic damage largely unaddressed. By targeting specific noncoding RNA pathways, future disease-modifying agents could directly arrest collagen overproduction. Additionally, measuring TUG1 expression in skin biopsies or circulating exosomes could serve as a non-invasive biomarker for disease progression and severity. Consequently, elevated TUG1 levels might identify patients at higher risk for severe cutaneous or visceral involvement. Moreover, monitoring TUG1 expression during therapeutic trials could help evaluate treatment responses accurately. Therefore, combining RNA-targeted anti-fibrotic therapies with existing immunomodulatory protocols could revolutionize clinical management. Clinicians should closely follow advancements in noncoding RNA therapeutics as novel drug candidates advance through developmental stages.

Future Directions in Noncoding RNA Therapeutics

Translating noncoding RNA research into clinical treatments requires overcoming key drug delivery challenges. Synthetic antisense oligonucleotides and microRNA mimics represent promising therapeutic modalities for blocking TUG1 sponging activity. However, achieving targeted delivery to dermal fibroblasts while minimizing systemic side effects remains crucial for patient safety. Advanced delivery platforms, including lipid nanoparticles and topical micro-needle arrays, offer effective solutions for localized administration. Furthermore, scientists are investigating whether the TUG1 axis drives fibrotic changes in internal organs, such as the lungs and gastrointestinal tract. If confirmed, targeting TUG1 could provide systemic protection against multi-organ fibrosis in systemic sclerosis. Consequently, ongoing interdisciplinary research promises to translate basic epigenetic discoveries into tangible clinical interventions. Ultimately, unraveling competing endogenous RNA networks empowers healthcare providers with innovative strategies to manage severe fibrotic autoimmune diseases effectively.

Frequently Asked Questions

What is the role of TUG1 in systemic sclerosis skin disease?

Long noncoding RNA TUG1 is significantly upregulated in dermal fibroblasts isolated from systemic sclerosis patients. It functions as a competing endogenous RNA that sponges miR-30d-3p and miR-30e-3p. This sponging action relieves post-transcriptional suppression on the transcription factor SNAI2, allowing SNAI2 to bind directly to the COL1A1 promoter. Consequently, TUG1 drives fibroblast proliferation, migration, and excessive collagen production, directly accelerating progressive dermal fibrosis in affected individuals.

How does SNAI2 contribute to excessive collagen synthesis?

SNAI2 acts as a crucial downstream transcription factor in the fibrotic signaling cascade. When TUG1 sponges protective miR-30d-3p and miR-30e-3p, SNAI2 protein levels rise markedly within dermal fibroblasts. Translocating to the cell nucleus, SNAI2 binds directly to specific promoter regions of the COL1A1 gene. This direct transcriptional activation triggers massive production of type I collagen, resulting in extracellular matrix accumulation, dermal thickening, and severe tissue stiffening.

Can targeting the TUG1 axis attenuate fibrosis in animal models?

Yes, preclinical animal studies demonstrate that knocking down Tug1 in bleomycin-induced mouse models effectively alleviates dermal fibrosis. Knocking down Tug1 restores intracellular levels of miR-30d-3p and miR-30e-3p, thereby suppressing SNAI2 expression and reducing COL1A1 transcription. Consequently, experimental animals show reduced skin thickness, decreased collagen deposition, and preserved dermal architecture. These results highlight the TUG1 axis as a viable therapeutic target for scleroderma.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

1. Zhu R et al. A novel LncRNA TUG1/miR-30d/e-3p/SNAI2 ceRNA axis drives dermal fibrosis in systemic sclerosis via direct transcriptional activation of COL1A1. Int Immunopharmacol. 2026 Aug 10. doi: undefined. PMID: 42574808.

2. Dermani FK et al. The role of long non-coding RNAs in systemic sclerosis and fibrotic diseases. J Cell Physiol. 2019;234(10):16750-16760.

3. Distler JH et al. Shared and distinct mechanisms of fibrosis in systemic sclerosis and organ-specific fibrotic diseases. Nat Rev Rheumatol. 2019;15(12):705-730.